www.fdanews.com/articles/108791-allos-enrolling-patients-in-bladder-cancer-trial
Allos Enrolling Patients in Bladder Cancer Trial
July 22, 2008
Patients with advanced or metastatic relapsed transitional cell carcinoma (TCC) of the urinary bladder are being enrolled in a Phase II study for Allo Therapeutics’ chemotherapeutic agent PDX.
The trial is testing PDX (pralatrexate) as a single agent or as a combination therapy for patients with TCC, which accounts for more than 90 percent of bladder cancers.
The open-label, single-arm, multicenter study is expected to enroll 41 patients from 20 sites worldwide. It will evaluate the drug’s effect on a complete or partial response, the company said.